Page 41 - ரோச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study OCREVUS-treated patients show highest adherence and persistence rates compared with other disease-modifying therapies (DMTs) in two-year U.S. claims analysis Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS(R) (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS

United statesUnited kingdomLevi garrawayEuropean unionAmerican academy of neurologyHead of global product developmentAmerican academyAnnual meetingChief medical officerGlobal productDisability status scaleNorth americaSouth americaMiddle eastEastern europeWorld health